FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
- Why You Should Speculate on Stocks
- Next Week’s Top IPO
- Cramer: 5 Earnings Reports to Watch Next Week
- More Americans Lighting Up? Buy This Stock
- What Happened to Cypress Semi?
- Lightning Round: Raytheon, Salesforce.com, Pepsi and More
- Lightning Round OT: Apache, Brocade, Allergan and More
- Cramer Goes One-on-One With Costco CEO
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
We already talked about what a great push the folks in Washington can be for a company, and Allscripts is a similar play.
No, there isn’t one particular politician that bought this stock the way Nancy Pelosi bought Clean Energy Fuels [CLNE
Loading...
()
]. Allscripts [MDRX
Loading...
()
] benefits thanks to what Chairman and CEO Glenn Tullman called “landmark legislation,” the newly signed Medicare bill.
Washington has decided to pay doctors to use Allscripts e-prescribing software for drug prescriptions. And on top of that, the government will start to penalize doctors who aren’t using e-prescribing systems, starting in a few years.
“So you can’t ask for a better endorsement than the government actually pushing your product,” Tullman said.
The CEO also took a minute to explain the expected acquisition of Mysis Healthcare Systems, saying the deal is on track for completion and that shareholders can expect about $5 a share cash dividend once the merger is closed.
Cramer expressed some concern about the stock dropping once that payout happens, but Tullman said that was inevitable given that some stockholders only bought MDRX for that dividend. “If you believe in the long-term premise,” he said, then that dip is a buying opportunity.
“This is a good story,” Cramer said. If the stock gets hit on the dividend payout, he might recommend MDRX again.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes